<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward D Chan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary alveolar proteinosis (PAP), also known as pulmonary alveolar phospholipoproteinosis, is a diffuse lung disease characterized by the accumulation of amorphous, periodic acid-Schiff (PAS)-positive lipoproteinaceous material in the distal air spaces [<a href="#rid1">1-3</a>]. There is little or no lung inflammation, and the underlying lung architecture is preserved. The lipoproteinaceous material is composed principally of surfactant phospholipid and apoproteins.</p><p>The etiology, pathogenesis, clinical manifestations, and diagnosis of PAP in adults will be reviewed here. The presentation and management of PAP in children and the treatment and prognosis of PAP in adults are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6351.html" rel="external">"Pulmonary alveolar proteinosis in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4356.html" rel="external">"Treatment and prognosis of pulmonary alveolar proteinosis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS AND CLASSIFICATION</span><span class="headingEndMark"> — </span>PAP is caused by a spectrum of disorders that negatively affect production and clearance of surfactant. Three main categories of PAP are recognized (<a class="graphic graphic_table graphicRef77313" href="/z/d/graphic/77313.html" rel="external">table 1</a>) [<a href="#rid2">2,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disruption of granulocyte-macrophage colony-stimulating factor signaling (autoimmune and hereditary PAP)</strong> – Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates clearance of surfactant by alveolar macrophages. Disorders that disrupt GM-CSF signalling include autoimmune PAP (the most common type of PAP in adults) and hereditary PAP due to recessive variants of the GM-CSF receptor alpha and beta genes (CSF2RA and CSF2RB). Antibodies to GM-CSF neutralize the effect of GM-CSF on alveolar macrophages, while genetic variants in the GM-CSF receptor impair signaling by intact GM-CSF. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders of surfactant production (congenital PAP)</strong> – Disorders of surfactant production are traditionally considered congenital PAP. These disorders often present in the neonatal period and encompass a number of genetic variants:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variants in surfactant proteins (SFTPB and SFTPC) [<a href="#rid5">5-7</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>Variants in proteins involved in the metabolism of surfactant (ATP-binding cassette, subfamily A [ABCA3]) [<a href="#rid8">8</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Variants in NK2 homeobox-1 (NKX2.1) thyroid transcription factor-1 (TTF1), which regulates transcription of SFTPB, SFTPC, and ABCA3 [<a href="#rid9">9</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Variants in the gene SLC7A7, which causes a defect in the plasma membrane transport of cationic amino acids (known as lysinuric protein intolerance). (See  <a class="medical medical_review" href="/z/d/html/6351.html" rel="external">"Pulmonary alveolar proteinosis in children", section on 'Congenital form'</a>.)</p><p></p><p class="bulletIndent1">Methionyl-tRNA synthetase (MARS) catalyzes the incorporation of methionine into tRNA and is critical for protein biosynthesis. Genetic variants of the MARS gene are associated with a rare childhood form of PAP prevalent on Réunion Island. (See  <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">"Genetic disorders of surfactant dysfunction", section on 'Related disorders'</a>.)</p><p></p><p class="bulletIndent1">Congenital alveolar proteinosis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6351.html" rel="external">"Pulmonary alveolar proteinosis in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary PAP</strong> – The secondary form of PAP develops in adulthood and is found in association with high level dust exposures (eg, silica, aluminum, titanium, indium-tin oxide) [<a href="#rid10">10-19</a>], hematologic dyscrasias (eg, myelodysplastic syndrome, GATA2 deficiency, hematologic malignancy) [<a href="#rid20">20-25</a>], and after allogeneic hematopoietic cell transplantation for myeloid malignancies [<a href="#rid26">26-28</a>]. (See  <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes"</a>.) </p><p></p><p class="bulletIndent1">While certain infections may give rise to a PAP-like pathology (eg, pneumocystosis), PAP may also increase vulnerability to such infections.</p><p></p><p class="bulletIndent1">In most cases, secondary PAP appears related to a relative deficiency of GM-CSF and related macrophage dysfunction [<a href="#rid10">10-14,19-21</a>]. High level dust inhalation appears to impair macrophage function through direct toxicity. Although indium-tin oxide inhalation has been associated with secondary PAP, in one report, one of two patients with indium-tin oxide-related PAP had elevated levels of antibodies to GM-CSF [<a href="#rid15">15</a>], raising the hypothesis that inhalation of an agent that causes PAP on lung pathology may be the consequence of an autoimmune process [<a href="#rid29">29-31</a>]. However, a subsequent study of 87 indium-tin oxide facility workers did not identify any workers with evidence of PAP or antibodies to GM-CSF [<a href="#rid32">32</a>]. Thus, it appears unlikely that PAP in this setting is an autoimmune process. </p><p></p><p>A few patients with cytologic or histopathologic evidence of PAP have reduced GM-CSF signalling, but no evidence of anti-GM-CSF antibodies or mutations in the GM-CSF receptor alpha or beta chains. These patients are considered to have unclassified PAP [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H754023497"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The various forms of PAP develop because of reduced granulocyte-macrophage colony-stimulating factor (GM-CSF) levels or function and/or impaired processing of surfactant by alveolar macrophages. (See <a class="local">'Definitions and classification'</a> above.)</p><p class="headingAnchor" id="H3"><span class="h2">Role of GM-CSF</span><span class="headingEndMark"> — </span>Several lines of evidence suggest that diminished GM-CSF protein or function plays a key role in PAP and is responsible for the observed impairments in surfactant processing [<a href="#rid4">4</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Genetically engineered mice that lack the GM-CSF gene have an accumulation of surfactant and surfactant apoprotein in the alveolar spaces similar to that seen in patients with PAP [<a href="#rid33">33</a>]. Reconstitution with the GM-CSF gene completely corrects the alveolar proteinosis in these GM-CSF knockout mice, as does treatment with aerosolized GM-CSF [<a href="#rid34">34,35</a>]. However, lack of GM-CSF production does not appear to play a major role in adult PAP [<a href="#rid36">36,37</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Defects in the heterodimeric GM-CSF receptor, which is composed of the ligand-binding alpha-chain (encoded by the CSF2RA gene) and the signal-transducing beta-chain (encoded by the CSF2RB gene), can lead to PAP or PAP-like disease. Mice that lack the GM-CSF receptor beta-chain develop a PAP-like syndrome [<a href="#rid38">38</a>]. Likewise, some congenital and rare acquired forms of PAP are associated with decreased or absent function of the GM-CSF receptor beta-chain [<a href="#rid36">36,39,40</a>]. Two separate reports of patients with familial PAP have found a genetic defect in the CSF2RA gene that results in decreased functional GM-CSF receptor alpha-chain [<a href="#rid41">41,42</a>]. As a result, there is greatly diminished GM-CSF binding to its receptor and reduced GM-CSF receptor signaling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Humoral autoimmunity leading to functional deficiency of GM-CSF is present in the vast majority of adult patients with acquired PAP [<a href="#rid43">43-51</a>]. In a series of 248 patients with a pathologic diagnosis of PAP, serum autoantibodies to GM-CSF were found in 223 patients (90 percent) classified as autoimmune PAP; of the remaining 25 with negative anti-GM-CSF antibody tests, 24 (10 percent) had diseases known to cause PAP (classified as secondary PAP) and 1 (&lt;1 percent) had unclassified PAP [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The role of antibodies to GM-CSF in the pathogenesis of PAP is further supported by studies of infusions of human immunoglobulin G1 (IgG1) containing anti-GM-CSF antibodies into nonhuman primates [<a href="#rid52">52,53</a>]. The primates developed milky bronchoalveolar lavage (BAL) fluid containing increased amounts of surfactant lipids and proteins. Surgical lung biopsies revealed alveoli filled with foamy, surfactant-filled alveolar macrophages. Evidence of decreased GM-CSF signaling was also noted. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Downstream effects of GM-CSF signaling impact proteins involved in surfactant clearance. Compared with normal controls, alveolar macrophages from patients with PAP demonstrate decreased levels of transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and the macrophage scavenger receptor CD36, which PPAR-gamma regulates [<a href="#rid54">54</a>]. PPAR-gamma and CD36 levels can be restored to normal following treatment with GM-CSF administered subcutaneously. The interrelationship between GM-CSF and PPAR-gamma may explain how GM-CSF deficiency could cause alveolar and macrophage accumulation of surfactant lipoprotein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The association of PAP with leukemia (eg, chronic myeloid leukemia) and allogeneic bone marrow transplantation may be reflective of relative GM-CSF deficiency [<a href="#rid21">21,55</a>]. Another possibility is the presence of concomitant anti-GM-CSF antibodies, described in one patient [<a href="#rid56">56</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Macrophage dysfunction</span><span class="headingEndMark"> — </span>Findings in patients and transgenic mice suggest that impaired processing of surfactant by alveolar macrophages contributes to the pathogenesis of PAP. Evidence that macrophage dysfunction (either primary or acquired) plays an important role in the initiation and propagation of disease includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Alveolar macrophage and type II cell clearance mechanisms are progressively overwhelmed by the accumulation of the surfactant-rich material, resulting in impaired phagocytosis and phagolysosome fusion [<a href="#rid5">5,57,58</a>]. Alveolar macrophages themselves, upon dying, may further contribute to the amorphous material [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alveolar macrophages obtained from patients with PAP after therapeutic whole lung lavage have greater migratory response to in vitro stimuli compared with macrophages from the same patients prior to the lavage [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other causes of acquired macrophage dysfunction, such as immunosuppressive drug therapy or hematologic malignancies, may explain the occasional finding of PAP associated with these disorders [<a href="#rid13">13,60</a>]. As an example, lysinuric protein intolerance, a rare autosomal recessive disorder that results in defective transport of cationic amino acids, is associated with both macrophage dysfunction and PAP [<a href="#rid60">60-64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PAP has been described in rare patients with family myelodysplastic syndrome due to deficiency of GATA2, which is in the family of zinc finger transcription factors and contributes to regulation of macrophage phagocytosis [<a href="#rid65">65,66</a>]. (See <a class="local">'Definitions and classification'</a> above and  <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial MDS/AML with mutated GATA2'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mice deficient in Bach2, a transcription repressor found in both innate and adaptive immune cells, have alveolar macrophage dysfunction and develop PAP despite having intact GM-CSF signaling [<a href="#rid67">67</a>]. Current lines of evidence suggest that the Bach2 deficiency must occur in both alveolar macrophages and CD4<sup>+</sup> T cells for PAP to occur, ultimately resulting in hyperactivated CD4<sup>+</sup> T cells that impair macrophage surfactant metabolism [<a href="#rid68">68</a>]. In other words, the normal function of Bach2 in alveolar macrophages is to prevent aberrant response to excessive T cell-induced inflammation and in T cells to prevent T cell hyperactivation. It has been hypothesized that Bach2 deficiency may account for some forms of secondary PAP but how hematopoietic malignancies or certain infections reduce Bach2 is not fully elucidated.</p><p></p><p class="headingAnchor" id="H3285756695"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>Upon histologic examination, the normal alveolar architecture is generally preserved, although the alveolar septa may be slightly thickened due to type II epithelial cell hyperplasia. There is typically little or no inflammatory cell infiltration. The terminal bronchioles and alveoli are filled with a flocculent and granular lipoproteinaceous material that stains pink with periodic acid-Schiff (PAS) stain (<a class="graphic graphic_picture graphicRef80653" href="/z/d/graphic/80653.html" rel="external">picture 1</a>). Within this lipoproteinaceous material, there are PAS-positive and oil red-O positive macrophages and scattered clefts of cholesterol crystals that may elicit a histiocytic giant-cell reaction [<a href="#rid69">69</a>].</p><p>While not commonly performed, electron microscopy of BAL fluid or lung tissue shows concentrically laminated structures called lamellar bodies. These bodies are comprised of phospholipids and are probably derived from the type II alveolar epithelial cells. Lamellar bodies may be found free in the alveolar airspaces, within alveolar macrophages, and in type II cells. A related ultrastructural finding of irregular concentric whorls (called tubular myelin) may represent the extracellular storage form or a breakdown product of surfactant.</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Among adults with PAP, the typical age at presentation is 40 to 50 years [<a href="#rid49">49,70,71</a>]. There is a male to female ratio of 2:1. Approximately 50 to 80 percent of patients with autoimmune PAP are current or former cigarette smokers [<a href="#rid2">2</a>].</p><p>A small number of patients also have other rheumatic diseases, including hemolytic anemia, polymyalgia rheumatica, ulcerative colitis, and granulomatosis with polyangiitis [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>PAP typically has an insidious onset in adults, although approximately one-third of affected patients are asymptomatic [<a href="#rid49">49</a>]. The major symptoms are progressive dyspnea on exertion (52 to 94 percent), cough (23 to 66 percent), sputum production (1 to 4 percent), fatigue (0 to 50 percent), weight loss (0 to 43 percent), and low-grade fever (1 to 15 percent) developing over weeks to months [<a href="#rid2">2,49,72-77</a>]. A non-productive cough is common, and expectoration of "chunky" gelatinous material may occasionally occur. </p><p>Among patients with secondary PAP due to myelodysplastic syndrome, fever is reported by 45 percent and cough by 42 percent [<a href="#rid2">2</a>].</p><p>Fever may occur in other patients with PAP due to superinfection with organisms such as <em>Nocardia</em>, <em>Mycobacteria</em>, and endemic or opportunistic fungi [<a href="#rid49">49,73,78</a>]. In a series of 248 patients with PAP, four patients had <em>Aspergillus</em> infection, three had <em>Mycobacterium tuberculosis</em>, and two had atypical mycobacterial infection [<a href="#rid49">49</a>]. In a separate series of 70 patients, 10 patients had respiratory infection (<em>Pneumocystis</em>, <em>E coli</em>, <em>Legionella</em>, and <em>Haemophilus influenza</em>) [<a href="#rid73">73</a>].  </p><p class="headingAnchor" id="H7"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The physical examination is often normal [<a href="#rid2">2</a>]. Crackles are present in approximately 50 percent of patients, but can be absent despite evidence of marked alveolar filling on radiographs, presumably because gas movement is absent in the completely fluid-filled distal airspaces [<a href="#rid70">70</a>]. Clubbing and cyanosis are present in about 25 percent [<a href="#rid49">49</a>]. </p><p class="headingAnchor" id="H3672506931"><span class="h2">Laboratory features</span><span class="headingEndMark"> — </span>Each of the types of PAP has characteristic laboratory abnormalities.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune PAP</strong> – Patients with autoimmune PAP will have positive testing for serum anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies, which are 100 percent sensitive and specific for autoimmune PAP [<a href="#rid2">2</a>]. While not used clinically, these patients have a reduced whole blood STAT5 phosphorylation, a measure of GM-CSF signaling.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary PAP</strong> – A complete blood count and differential is obtained to evaluate for hematologic malignancy or myelodysplastic syndrome. Testing for a GATA2 genetic variant may be appropriate in patients with the combination of familial myelodysplastic syndrome and PAP. (See <a class="local">'Macrophage dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary PAP due to GM-CSF receptor defects</strong> – Patients with hereditary PAP due to rare genetic variants in the GM-CSF receptor alpha or beta subunits (CSF2RA and CSF2RB) have an elevated serum level of GM-CSF, reduced serum STAT5-PI, and abnormal receptor function [<a href="#rid2">2</a>]. Sequencing confirms the presence of recessive genetic variants CSF2RA and CSF2RB. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PAP due to surfactant production disorders</strong> – Patients with PAP due to a surfactant-related gene variants (eg, surfactant proteins B and C, ATP-binging cassette A [ABCA3], NK homeobox-1 [NKX2,1]) typically have a normal STAT5-phosphorylation. However, these disorders typically appear in childhood, so adults with PAP generally do not require testing for surfactant gene variants. (See  <a class="medical medical_review" href="/z/d/html/6351.html" rel="external">"Pulmonary alveolar proteinosis in children", section on 'Laboratory tests'</a>.)</p><p></p><p>Other laboratory abnormalities include polycythemia, hypergammaglobulinemia, and increased lactate dehydrogenase (LDH) levels, although these findings are nonspecific [<a href="#rid79">79</a>]. </p><p>A number of biomarkers have been associated with PAP, but none are sufficiently sensitive or specific to be useful diagnostically. Elevated levels of lung surfactant proteins A and D (SP-A and SP-D), several tumor markers (carcinoembryonic antigen [CEA], carbohydrate antigens sialyl Lewis-a [CA 19-9], and sialyl SSEA-1 [SLX]), and Kerbs von Lungren 6 antigen (KL-6) have been found in serum from patients with PAP, but have unclear diagnostic utility [<a href="#rid2">2,49,80-87</a>]. Bronchoalveolar lavage (BAL) biomarkers are described below. (See <a class="local">'Flexible bronchoscopy'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Imaging</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest radiograph</strong> – Bilateral symmetric alveolar opacities located centrally in mid and lower lung zones are typical, often in a "bat wing" distribution (<a class="graphic graphic_diagnosticimage graphicRef62269" href="/z/d/graphic/62269.html" rel="external">image 1</a>). Additional findings include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asymmetric, unilateral, or nodular patterns may be present [<a href="#rid88">88</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Despite the process being alveolar in distribution, air bronchograms are rare</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A thin lucent band may sharply outline the diaphragm and the heart, consistent with sparing of the lung immediately adjacent to these structures</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Segmental atelectasis can occur due to bronchiolar obstruction by thick lipoproteinaceous material [<a href="#rid13">13</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Incomplete alveolar filling may result in reticular markings despite the predominant filling of alveoli observed pathologically [<a href="#rid89">89</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In chronic cases, focal areas of fibrosis and even extensive pulmonary fibrosis leading to respiratory insufficiency have been rarely reported [<a href="#rid90">90</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-resolution computed tomography (HRCT)</strong> – HRCT typically reveals ground-glass opacification, predominantly in a homogeneous distribution. There may also be thickened intralobular structures and interlobular septa in typical polygonal shapes superimposed on ground glass opacities, referred to as "crazy-paving" (<a class="graphic graphic_table graphicRef111425" href="/z/d/graphic/111425.html" rel="external">table 2</a> and <a class="graphic graphic_diagnosticimage graphicRef58662" href="/z/d/graphic/58662.html" rel="external">image 2</a>) [<a href="#rid69">69,76,77,91</a>]. In a series of 42 patients, a patchy, geographic pattern with crazy-paving was common among patients with autoimmune PAP, whereas a pattern of diffuse ground glass opacity without crazy-paving was more common among patients with secondary PAP [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1">However, crazy-paving is not specific for PAP and can also be observed in patients with the acute respiratory distress syndrome, organizing pneumonia, lipoid pneumonia, acute interstitial pneumonia/diffuse alveolar damage (AIP/DAD), drug-related hypersensitivity reactions, and AIP/DAD superimposed on usual interstitial pneumonitis [<a href="#rid92">92,93</a>]. (See  <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">"High resolution computed tomography of the lungs", section on 'Ground-glass opacification'</a>.)</p><p></p><p class="bulletIndent1">Rarely, PAP with concomitant lung fibrosis may occur and appear to be associated with underlying GATA2 mutation [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Pulmonary function tests</span><span class="headingEndMark"> — </span>Pulmonary function tests typically demonstrate a reduction in the diffusing capacity for carbon monoxide (DLCO) that may be isolated or accompanied by a restrictive ventilatory defect (decrease in forced vital capacity) [<a href="#rid49">49,94</a>]. When present, the decrement in DLCO is often out of proportion to the degree of reduction in lung volume and correlates well with other measures of disease severity, such as symptoms and reduced arterial tension of oxygen (PaO<sub>2</sub>) [<a href="#rid49">49</a>]. Varying degrees of hypoxemia and compensated respiratory alkalosis are also common and frequently worsen with exercise. An elevated right-to-left shunt fraction is usually present.</p><p class="headingAnchor" id="H1105235940"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H3281899323"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Our diagnostic algorithm for suspected PAP in an adult is shown in the figure (<a class="graphic graphic_algorithm graphicRef111428" href="/z/d/graphic/111428.html" rel="external">algorithm 1</a>). When findings suggestive of PAP are noted on high-resolution computed tomography (HRCT) scan in patients with a compatible clinical presentation, one of the first steps is to assess the severity of respiratory impairment with pulmonary function tests, as more severe impairment dictates a more rapid pace of evaluation and may limit the invasiveness of testing. (See <a class="local">'Pulmonary function tests'</a> above.)</p><p>The next step is to evaluate for secondary PAP by reviewing the history of exposures and checking the complete blood count for evidence of hematologic malignancy or myelodysplastic syndrome. </p><p>We then proceed to flexible bronchoscopy to obtain bronchoalveolar lavage (BAL) fluid and, when possible, transbronchial lung biopsies (TBLB). BAL fluid characterized by a milky-opaque appearance is strongly suggestive of PAP and the subsequent evaluation focuses on determining the type of PAP. </p><p>In the absence of typical features on BAL or TBLB, the next step is usually surgical lung biopsy to determine whether the BAL was falsely negative or whether another process can be diagnosed. In the largest series of PAP, the diagnosis was made by HRCT and BAL in 59 percent; HRCT, BAL, and transbronchial biopsy in 34 percent; and video-assisted thoracoscopic biopsy in 7 percent [<a href="#rid49">49</a>].</p><p>Laboratory testing for antibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) may be performed at the same time as bronchoscopy or subsequent to identification of typical BAL features (eg, opaque or milky appearance, copious periodic acid-Schiff [PAS]-positive material in and around alveolar macrophages), depending on the availability of the testing. As noted above, typical HRCT, BAL features in combination with positive serologic testing for anti-GM-CSF antibodies provide a confident diagnosis of autoimmune PAP. (See <a class="local">'Laboratory features'</a> above.)</p><p>For patients who have HRCT and BAL evidence of PAP, but do not have serum antibodies to GM-CSF, a serum GM-CSF level is obtained. If serum GM-CSF is elevated, the function of the GM-CSF receptor should be assessed. If this is abnormal, sequencing for genetic variants of the receptor subunits (hereditary PAP) is performed by a specialty laboratory. </p><p>If the HRCT and BAL suggest PAP, but the GM-CSF serum level is normal and antibodies to GM-CSF are absent, a surgical lung biopsy is needed for definitive diagnosis of PAP, which is then considered to be "unclassified" [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1220475241"><span class="h2">Exclusion of causes of secondary PAP</span><span class="headingEndMark"> — </span>We normally obtain a complete blood count and differential early in the evaluation of interstitial lung disease. This is especially important in suspected PAP because of the occasional association of PAP with hematologic malignancies and myelodysplasia [<a href="#rid20">20-25</a>].</p><p>Other secondary causes of PAP, such as high level dust exposures (eg, silica, aluminum, titanium, indium-tin oxide) are excluded by a careful occupational history [<a href="#rid95">95</a>]. </p><p class="headingAnchor" id="H4140889446"><span class="h2">Flexible bronchoscopy</span><span class="headingEndMark"> — </span>Flexible bronchoscopy with BAL and, when possible, TBLB is a key step in the diagnosis of PAP. TBLB is generally performed after the BAL and in a different subsegment. Among 36 patients with autoimmune or secondary PAP, the diagnosis of PAP was based on bronchoscopic findings in 30 (83 percent); BAL was used alone in 18 (50 percent) and combined with TBLB in 11 (30 percent) [<a href="#rid73">73</a>]. In a separate series of 248 patients with PAP, the diagnosis was established by BAL in 146 (59 percent) and BAL plus TBLB in 84 (34 percent) [<a href="#rid49">49</a>]. In both series, the diagnosis was made by surgical lung biopsy in the remainder. (See <a class="local">'Surgical lung biopsy'</a> below.)</p><p>Characteristic BAL findings of PAP include:</p><p class="bulletIndent1"><span class="glyph">●</span>An opaque or milky appearance due to the abundant lipoproteinaceous material, which may settle upon standing</p><p class="bulletIndent1"><span class="glyph">●</span>Cytopathology demonstrating engorgement of alveolar macrophages with PAS-positive material on a background of flocculent proteinaceous material that is similarly PAS positive (<a class="graphic graphic_picture graphicRef78010" href="/z/d/graphic/78010.html" rel="external">picture 2</a>) with large acellular eosinophilic bodies in a background of eosinophilic granules (<a class="graphic graphic_picture graphicRef80205" href="/z/d/graphic/80205.html" rel="external">picture 3</a>) </p><p class="bulletIndent1"><span class="glyph">●</span>Papanicolaou-staining reveals large globules that are green, orange, or orange with a green rim [<a href="#rid96">96</a>]</p><p></p><p>To exclude infection that might cause a clinical picture similar to PAP or that is concurrent with PAP, BAL samples are sent for special stains and cultures for opportunistic infections (eg, <em>Pneumocystis</em>, <em>Nocardia</em>, mycobacteria, fungi). Differential cell counts are nonspecific in PAP, but may be useful for identifying other conditions. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Differential diagnosis'</a> below.)</p><p>Certain biomarkers have been identified in BAL fluid and are similar to those identified in blood samples (see <a class="local">'Laboratory features'</a> above). In a series of 15 patients with PAP compared to control patients with other interstitial lung diseases, BAL levels of chemokine (C-C) motif ligand 2 (CCL2), Kerbs von Lungren 6 antigen (KL-6), and surfactant protein D were increased [<a href="#rid87">87</a>]. Higher levels of KL-6 in both the BAL fluid and blood correlated significantly with higher serum LDH levels, lower arterial tension of oxygen (PaO<sub>2</sub>), and a higher alveolar-arterial oxygen gradient [<a href="#rid87">87</a>]. Further studies are needed to determine the clinical utility of these tests.</p><p class="headingAnchor" id="H2380817790"><span class="h2">Anti-GM-CSF titer</span><span class="headingEndMark"> — </span>Measurement of serum anti-GM-CSF antibody is an important step in the diagnosis of autoimmune PAP. In the absence of any known secondary cause of PAP, an elevated serum anti-GM-CSF titer is 100 percent sensitive and 91 to 98 percent specific for the diagnosis of autoimmune PAP [<a href="#rid45">45,46,97</a>]. Low levels of GM-CSF antibodies can be observed in healthy individuals [<a href="#rid97">97</a>]. Serum samples generally need to be sent to a specialty laboratory for testing, such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cincinnatichildrens.org%2Fservice%2Fr%2Frare-lung%2Fprofessionals%2Fpap-lab&amp;token=033Sa9HEybeKcN7z4XWHqzNDR94KQabUImyF3qDnNMF6lsmm8%2FGtlcX1GLLNAt7e%2F91OlBUVK%2F7gyhCdmkZN9kLqkMRcHgt6pDLOFKao5jM%3D&amp;TOPIC_ID=4373" target="_blank">Pulmonary Alveolar Proteinosis laboratory at Cincinnati Children's Hospital</a>.</p><p>BAL fluid levels of anti-GM-CSF antibodies correlate better with the severity of PAP compared to serum titers [<a href="#rid98">98</a>]. Serial measurements of BAL or serum anti-GM-CSF antibodies may prove useful in monitoring disease activity and response to treatment, although data to support this practice are limited [<a href="#rid99">99,100</a>].</p><p class="headingAnchor" id="H3670728889"><span class="h2">Surgical lung biopsy</span><span class="headingEndMark"> — </span>Surgical lung biopsy is needed to establish a diagnosis of PAP in approximately 10 to 20 percent of patients due to nondiagnostic findings on HRCT, BAL, and TBLB [<a href="#rid2">2,49,73</a>]. (See  <a class="medical medical_review" href="/z/d/html/15141.html" rel="external">"Overview of minimally invasive thoracic surgery"</a>.)</p><p class="headingAnchor" id="H1427846634"><span class="h2">Other specialty laboratory testing</span><span class="headingEndMark"> — </span>Additional specialty laboratory testing may be needed for patients who have HRCT and BAL evidence of PAP, but do not have serum antibodies to GM-CSF. In these patients, abnormal GM-CSF receptor function or an as yet unclassified defect may be present. A serum GM-CSF level helps to guide the evaluation. An elevated level of GM-CSF suggests dysfunction of the GM-CSF receptor, which can be assessed by signalling analysis. If this is abnormal, sequencing for genetic variants of the receptor subunits (hereditary PAP) can be performed. As these patients are rare, testing is performed at a specialty laboratory such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cincinnatichildrens.org%2Fservice%2Fr%2Frare-lung%2Fprofessionals%2Fpap-lab&amp;token=033Sa9HEybeKcN7z4XWHqzNDR94KQabUImyF3qDnNMF6lsmm8%2FGtlcX1GLLNAt7e%2F91OlBUVK%2F7gyhCdmkZN9kLqkMRcHgt6pDLOFKao5jM%3D&amp;TOPIC_ID=4373" target="_blank">Pulmonary Alveolar Proteinosis laboratory at Cincinnati Children's Hospital</a>.</p><p class="headingAnchor" id="H2036688526"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A definitive diagnosis of PAP in an adult is based on the presence of typical histopathologic features of PAP (flocculent and granular periodic acid-Schiff [PAS] positive lipoproteinaceous material stain is demonstrated filling terminal bronchioles and alveoli) on a transbronchial or surgical lung biopsy (<a class="graphic graphic_picture graphicRef80653" href="/z/d/graphic/80653.html" rel="external">picture 1</a>) (see <a class="local">'Pathology'</a> above). Alternatively, a confident diagnosis of autoimmune PAP can be made based on typical features on high-resolution computed tomography (HRCT) and bronchoalveolar lavage (eg, abundant PAS-positive proteinaceous material in and around alveolar macrophages) in combination with demonstration of granulocyte macrophage-colony stimulating factor (GM-CSF) antibodies in the serum [<a href="#rid2">2,49,72,73,101-106</a>]. (See <a class="local">'Imaging'</a> above and <a class="local">'Flexible bronchoscopy'</a> above.)</p><p>The diagnosis of secondary PAP is based on typical findings on HRCT and BAL combined with a history of high level dust exposure (eg, silica, aluminum, titanium, indium-tin oxide), demonstration of hematologic abnormalities (myelodysplasia or malignancy), or history of hematopoietic cell transplantation. (See <a class="local">'Definitions and classification'</a> above and <a class="local">'Overview'</a> above.)</p><p>Hereditary PAP due to genetic variants in the GM-CSF receptor alpha or beta subunits (CSF2RA and CSF2RB) are rare and the diagnosis is based on demonstration of abnormal GM-CSF receptor function and gene sequencing by a specialty laboratory. (See <a class="local">'Other specialty laboratory testing'</a> above.)</p><p class="headingAnchor" id="H481903297"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of adult PAP includes those disorders with similar radiographic manifestations, such as a mosaic pattern of ground glass opacities, sometimes associated with "crazy-paving" due to thickened intralobular structures and interlobular septa (see <a class="local">'Imaging'</a> above). These disorders include infection (eg, due to <em>Pneumocystis jirovecii </em>or <em>Mycoplasma</em>), cardiogenic and noncardiogenic pulmonary edema, lipoid pneumonia, drug-related hypersensitivity reactions, organizing pneumonia, acute interstitial pneumonia (AIP), and diffuse alveolar damage superimposed on usual interstitial pneumonitis (UIP).</p><p>In addition to the absence of periodic acid-Schiff (PAS) positive proteinaceous material on BAL, the following features help to distinguish among the alternative diagnostic possibilities:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiogenic or noncardiogenic pulmonary edema</strong> – The clinical presentation of fulminant respiratory failure with diffuse alveolar opacities would favor cardiogenic or noncardiogenic pulmonary edema (eg, due to acute respiratory distress syndrome), or AIP. Cardiogenic pulmonary edema can usually be excluded by the absence of clinical evidence of fluid overload, a normal brain natriuretic peptide, and normal echocardiogram. These processes are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema"</a> and  <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">"Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">"Acute interstitial pneumonia (Hamman-Rich syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections and ARDS</strong> – Diffuse lung infections, such as <em>Pneumocystis jirovecii </em>pneumonia, coronavirus-19 pneumonia, influenza, and causes of diffuse alveolar damage (acute respiratory distress syndrome)<em> </em>typically have a more acute onset than PAP. While fever is more commonly associated with infection than with PAP, some patients with PAP have fever without identifiable infection and infection can complicate the course of PAP. The diagnosis is generally made on microbiologic studies of the blood and BAL. (See  <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"</a> and  <a class="medical medical_review" href="/z/d/html/1609.html" rel="external">"Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults", section on 'Pneumonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipoid pneumonia</strong> – Lipoid pneumonia secondary to aspiration of lipoid material (eg, <a class="drug drug_general" data-topicid="10213" href="/z/d/drug information/10213.html" rel="external">mineral oil</a>) can present with ground-glass opacities and interlobular septal thickening in a "crazy paving" pattern, mimicking PAP, although basilar peribronchovascular areas of ground glass or consolidative opacities (sometimes with low attenuation) are more typical [<a href="#rid107">107</a>]. BAL demonstration of large numbers of lipid-laden macrophages would suggest lipoid pneumonia. (See  <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic interstitial pneumonias</strong> – An HRCT appearance of a predominantly subpleural distribution of disease and sparse honeycombing would favor acute interstitial pneumonia or idiopathic pulmonary fibrosis over PAP. Organizing pneumonia is occasionally associated with crazy-paving, but the BAL would not show the copious PAS positive material typical of PAP. (See  <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">"Acute interstitial pneumonia (Hamman-Rich syndrome)"</a> and  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced pneumonitis</strong> – Drug-induced pneumonitis can present with similar time course and imaging characteristics as PAP. It should be suspected in patients with exposure to medications such as <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, taxanes, and <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>. BAL findings in drug-induced pneumonitis will not show abundant PAS positive material. (See  <a class="medical medical_review" href="/z/d/html/4364.html" rel="external">"Amiodarone pulmonary toxicity"</a> and  <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a> and  <a class="medical medical_review" href="/z/d/html/4371.html" rel="external">"Nitrofurantoin-induced pulmonary injury"</a> and  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a> and  <a class="medical medical_review" href="/z/d/html/4355.html" rel="external">"Taxane-induced pulmonary toxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute exacerbations of interstitial lung disease</strong> – Although diffuse pulmonary involvement and severely compromised DLCO are present in acute exacerbations of interstitial lung disease, the presence of additional interstitial fibrotic features, including subpleural septal thickening and honeycombing, distinguish the condition. (See  <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">"Acute exacerbations of idiopathic pulmonary fibrosis"</a>.)</p><p></p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Pulmonary alveolar proteinosis (PAP), also known as pulmonary alveolar phospholipoproteinosis, is characterized by the intra-alveolar accumulation of surfactant phospholipid and apoproteins. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and classification</strong> – PAP is caused by a spectrum of disorders in surfactant homeostasis that affect production and clearance of surfactant. Three main categories of PAP are recognized, disruption of granulocyte-macrophage-colony stimulating factor (GM-CSF) signaling (eg, autoimmune PAP), disorders of surfactant production (eg, congenital PAP), and secondary PAP (eg, inhalant exposures, hematologic disorders) (<a class="graphic graphic_table graphicRef77313" href="/z/d/graphic/77313.html" rel="external">table 1</a>). Autoimmune PAP due to granulocyte macrophage-colony stimulating factor (GM-CSF) antibodies is the most common type in adults. (See <a class="local">'Definitions and classification'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Symptoms and physical examination</strong> – Among adults with PAP, the typical age at presentation is 40 to 50 years and twice as many men are affected as women. The major symptoms are progressive dyspnea, cough, sputum production, fatigue, and weight loss, which develop over weeks to months. The physical examination may be normal or may show crackles and, less commonly, clubbing or cyanosis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging</strong> – Chest radiographs show bilateral symmetric alveolar opacities located centrally in mid and lower lung zones, sometimes resulting in a "bat wing" distribution. High-resolution computed tomography (HRCT) reveals ground-glass opacification that typically spares the periphery and may have a "crazy-paving" appearance due to thickening of the interlobular and intralobular septa. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic Evaluation</strong> – When typical features of PAP are noted on chest radiograph and HRCT in a patient with a compatible clinical presentation, we follow a diagnostic algorithm to confirm the diagnosis and identify the exact etiology (<a class="graphic graphic_algorithm graphicRef111428" href="/z/d/graphic/111428.html" rel="external">algorithm 1</a>). (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History and peripheral smear</strong> – First, we evaluate for secondary causes of PAP by history (eg, dust exposure, hematopoietic cell transplantation) and examination of the peripheral blood for evidence of myelodysplasia or hematologic malignancy, as the management of these patients depends on the underlying cause. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bronchoscopy</strong> – The next step is to perform flexible bronchoscopy with bronchoalveolar lavage (BAL) and, if possible, transbronchial biopsy. Typical BAL fluid in PAP has an opaque or milky appearance due to abundant lipoproteinaceous material. Cytologic examination of BAL reveals copious, flocculent periodic acid Schiff (PAS)-positive material surrounding alveolar macrophages engorged with the same material. These features are strongly suggestive of PAP and the subsequent evaluation focuses on determining the type of PAP. (See <a class="local">'Flexible bronchoscopy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>GM-CSF antibody testing</strong> – Adults with a strong suspicion for PAP based in HRCT and BAL should have serologic testing for antibodies to GM-CSF. This testing is available in specialized laboratories. (See <a class="local">'Anti-GM-CSF titer'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Additional steps in patients with negative GM-CSF antibodies</strong> – For patients who have HRCT and BAL evidence of PAP, but do not have serum antibodies to GM-CSF, we obtain a serum GM-CSF level is obtained. If serum GM-CSF is elevated, the function of the GM-CSF receptor should be assessed. If this is abnormal, sequencing for genetic variants of the receptor subunits (hereditary PAP) can be performed in specialized laboratories. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent2">If the HRCT and BAL suggest PAP, but antibodies to GM-CSF are absent and the GM-CSF serum level is normal, a surgical lung biopsy is needed for definitive diagnosis of PAP, which is then considered to be "unclassified." (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of adult PAP involves those disorders with similar radiographic manifestations, such as infection (eg, due to <em>Pneumocystis jirovecii</em> and <em>Mycoplasma</em>), cardiogenic and noncardiogenic pulmonary edema, lipoid pneumonia, drug-related hypersensitivity reactions, organizing pneumonia, acute interstitial pneumonia (AIP), and acute exacerbations of fibrotic interstitial lung diseases. (See <a class="local">'Differential diagnosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ROSEN SH, CASTLEMAN B, LIEBOW AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258:1123.</a></li><li><a class="nounderline abstract_t">Suzuki T, Trapnell BC. Pulmonary Alveolar Proteinosis Syndrome. Clin Chest Med 2016; 37:431.</a></li><li><a class="nounderline abstract_t">Kumar A, Abdelmalak B, Inoue Y, Culver DA. Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. Lancet Respir Med 2018; 6:554.</a></li><li><a class="nounderline abstract_t">Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 2010; 135:223.</a></li><li><a class="nounderline abstract_t">Brasch F, Birzele J, Ochs M, et al. Surfactant proteins in pulmonary alveolar proteinosis in adults. Eur Respir J 2004; 24:426.</a></li><li><a class="nounderline abstract_t">Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93:1860.</a></li><li><a class="nounderline abstract_t">Mildenberger E, deMello DE, Lin Z, et al. Focal congenital alveolar proteinosis associated with abnormal surfactant protein B messenger RNA. Chest 2001; 119:645.</a></li><li><a class="nounderline abstract_t">Mulugeta S, Gray JM, Notarfrancesco KL, et al. Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3. J Biol Chem 2002; 277:22147.</a></li><li><a class="nounderline abstract_t">Salerno T, Peca D, Menchini L, et al. Respiratory insufficiency in a newborn with congenital hypothyroidism due to a new mutation of TTF-1/NKX2.1 gene. Pediatr Pulmonol 2014; 49:E42.</a></li><li><a class="nounderline abstract_t">Buechner HA, Ansari A. Acute silico-proteinosis. A new pathologic variant of acute silicosis in sandblasters, characterized by histologic features resembling alveolar proteinosis. Dis Chest 1969; 55:274.</a></li><li><a class="nounderline abstract_t">Miller RR, Churg AM, Hutcheon M, Lom S. Pulmonary alveolar proteinosis and aluminum dust exposure. Am Rev Respir Dis 1984; 130:312.</a></li><li><a class="nounderline abstract_t">Keller CA, Frost A, Cagle PT, Abraham JL. Pulmonary alveolar proteinosis in a painter with elevated pulmonary concentrations of titanium. Chest 1995; 108:277.</a></li><li><a class="nounderline abstract_t">Prakash UB, Barham SS, Carpenter HA, et al. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc 1987; 62:499.</a></li><li><a class="nounderline abstract_t">McDonald JW, Alvarez F, Keller CA. Pulmonary alveolar proteinosis in association with household exposure to fibrous insulation material. Chest 2000; 117:1813.</a></li><li><a class="nounderline abstract_t">Cummings KJ, Donat WE, Ettensohn DB, et al. Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med 2010; 181:458.</a></li><li><a class="nounderline abstract_t">Cummings KJ, Nakano M, Omae K, et al. Indium lung disease. Chest 2012; 141:1512.</a></li><li><a class="nounderline abstract_t">Shaughnessy GF, Lee AS. Pulmonary Alveolar Proteinosis, Barbecue Smoke, and Granulocyte-macrophage Colony-stimulating Factor Therapy. Am J Med 2016; 129:e7.</a></li><li><a class="nounderline abstract_t">Ishii H, Tazawa R, Kaneko C, et al. Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan. Eur Respir J 2011; 37:465.</a></li><li><a class="nounderline abstract_t">Chew R, Nigam S, Sivakumaran P. Alveolar proteinosis associated with aluminium dust inhalation. Occup Med (Lond) 2016; 66:492.</a></li><li><a class="nounderline abstract_t">Cordonnier C, Fleury-Feith J, Escudier E, et al. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 1994; 149:788.</a></li><li><a class="nounderline abstract_t">Tsushima K, Koyama S, Saitou H, et al. Pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. Respiration 1999; 66:173.</a></li><li><a class="nounderline abstract_t">Ballerie A, Nimubona S, Meunier C, et al. Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency. Eur Respir J 2016; 48:1510.</a></li><li><a class="nounderline abstract_t">Chaulagain CP, Pilichowska M, Brinckerhoff L, et al. Secondary pulmonary alveolar proteinosis in hematologic malignancies. Hematol Oncol Stem Cell Ther 2014; 7:127.</a></li><li><a class="nounderline abstract_t">Griese M, Zarbock R, Costabel U, et al. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulm Med 2015; 15:87.</a></li><li><a class="nounderline abstract_t">Chung JH, Pipavath SJ, Myerson DH, Godwin D. Secondary pulmonary alveolar proteinosis: a confusing and potentially serious complication of hematologic malignancy. J Thorac Imaging 2009; 24:115.</a></li><li><a class="nounderline abstract_t">Sharma S, Nadrous HF, Peters SG, et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 2005; 128:1385.</a></li><li><a class="nounderline abstract_t">Pidala J, Khalil F, Fernandez H. Pulmonary alveolar proteinosis following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2011; 46:1480.</a></li><li><a class="nounderline abstract_t">Tomonari A, Shirafuji N, Iseki T, et al. Acquired pulmonary alveolar proteinosis after umbilical cord blood transplantation for acute myeloid leukemia. Am J Hematol 2002; 70:154.</a></li><li><a class="nounderline abstract_t">Masuko H, Hizawa N, Chonan T, et al. Indium-tin oxide does not induce GM-CSF autoantibodies. Am J Respir Crit Care Med 2011; 184:741; author reply 741.</a></li><li><a class="nounderline abstract_t">Costabel U, Nakata K. Pulmonary alveolar proteinosis associated with dust inhalation: not secondary but autoimmune? Am J Respir Crit Care Med 2010; 181:427.</a></li><li><a class="nounderline abstract_t">Lison D, Delos M. Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med 2010; 182:578; author reply 578.</a></li><li><a class="nounderline abstract_t">Cummings KJ, Virji MA, Trapnell BC, et al. Early changes in clinical, functional, and laboratory biomarkers in workers at risk of indium lung disease. Ann Am Thorac Soc 2014; 11:1395.</a></li><li><a class="nounderline abstract_t">Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264:713.</a></li><li><a class="nounderline abstract_t">Huffman JA, Hull WM, Dranoff G, et al. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 1996; 97:649.</a></li><li><a class="nounderline abstract_t">Reed JA, Ikegami M, Cianciolo ER, et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999; 276:L556.</a></li><li><a class="nounderline abstract_t">Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003; 349:2527.</a></li><li><a class="nounderline abstract_t">Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161:1294.</a></li><li><a class="nounderline abstract_t">Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2:211.</a></li><li><a class="nounderline abstract_t">Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100:2211.</a></li><li><a class="nounderline abstract_t">Bewig B, Wang XD, Kirsten D, et al. GM-CSF and GM-CSF beta c receptor in adult patients with pulmonary alveolar proteinosis. Eur Respir J 2000; 15:350.</a></li><li><a class="nounderline abstract_t">Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205:2711.</a></li><li><a class="nounderline abstract_t">Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205:2703.</a></li><li><a class="nounderline abstract_t">Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190:875.</a></li><li><a class="nounderline abstract_t">Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004; 103:1089.</a></li><li><a class="nounderline abstract_t">Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 162:658.</a></li><li><a class="nounderline abstract_t">Bonfield TL, Russell D, Burgess S, et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27:481.</a></li><li><a class="nounderline abstract_t">Latzin P, Tredano M, Wüst Y, et al. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60:39.</a></li><li><a class="nounderline abstract_t">Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001; 163:524.</a></li><li><a class="nounderline abstract_t">Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177:752.</a></li><li><a class="nounderline abstract_t">Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007; 356:567.</a></li><li><a class="nounderline abstract_t">Doerschuk CM. Pulmonary alveolar proteinosis--is host defense awry? N Engl J Med 2007; 356:547.</a></li><li><a class="nounderline abstract_t">Sakagami T, Uchida K, Suzuki T, et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 2009; 361:2679.</a></li><li><a class="nounderline abstract_t">Sakagami T, Beck D, Uchida K, et al. Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med 2010; 182:49.</a></li><li><a class="nounderline abstract_t">Bonfield TL, Farver CF, Barna BP, et al. Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003; 29:677.</a></li><li><a class="nounderline abstract_t">Ohmachi K, Ogiya D, Morita F, et al. Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase. Tokai J Exp Clin Med 2008; 33:146.</a></li><li><a class="nounderline abstract_t">Yoshimura M, Kojima K, Tomimasu R, et al. ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia. Int J Hematol 2014; 100:611.</a></li><li><a class="nounderline abstract_t">Alberti A, Luisetti M, Braschi A, et al. Bronchoalveolar lavage fluid composition in alveolar proteinosis. Early changes after therapeutic lavage. Am J Respir Crit Care Med 1996; 154:817.</a></li><li><a class="nounderline abstract_t">Gonzalez-Rothi RJ, Harris JO. Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages. Chest 1986; 90:656.</a></li><li><a class="nounderline abstract_t">Hoffman RM, Dauber JH, Rogers RM. Improvement in alveolar macrophage migration after therapeutic whole lung lavage in pulmonary alveolar proteinosis. Am Rev Respir Dis 1989; 139:1030.</a></li><li><a class="nounderline abstract_t">Poletti V, Costabel U, Casoni GL, et al. Rare infiltrative lung diseases: a challenge for clinicians. Respiration 2004; 71:431.</a></li><li><a class="nounderline abstract_t">Santamaria F, Brancaccio G, Parenti G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 2004; 145:268.</a></li><li><a class="nounderline abstract_t">Palacín M, Borsani G, Sebastio G. The molecular bases of cystinuria and lysinuric protein intolerance. Curr Opin Genet Dev 2001; 11:328.</a></li><li><a class="nounderline abstract_t">Parto K, Mäki J, Pelliniemi LJ, Simell O. Abnormal pulmonary macrophages in lysinuric protein intolerance. Ultrastructural, morphometric, and x-ray microanalytic study. Arch Pathol Lab Med 1994; 118:536.</a></li><li><a class="nounderline abstract_t">Parto K, Kallajoki M, Aho H, Simell O. Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients. Hum Pathol 1994; 25:400.</a></li><li><a class="nounderline abstract_t">Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123:809.</a></li><li><a class="nounderline abstract_t">Marciano BE, Olivier KN, Folio LR, et al. Pulmonary Manifestations of GATA2 Deficiency. Chest 2021; 160:1350.</a></li><li><a class="nounderline abstract_t">Nakamura A, Ebina-Shibuya R, Itoh-Nakadai A, et al. Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function. J Exp Med 2013; 210:2191.</a></li><li><a class="nounderline abstract_t">Ebina-Shibuya R, Matsumoto M, Kuwahara M, et al. Inflammatory responses induce an identity crisis of alveolar macrophages, leading to pulmonary alveolar proteinosis. J Biol Chem 2017; 292:18098.</a></li><li><a class="nounderline abstract_t">Holbert JM, Costello P, Li W, et al. CT features of pulmonary alveolar proteinosis. AJR Am J Roentgenol 2001; 176:1287.</a></li><li><a class="nounderline abstract_t">Goldstein LS, Kavuru MS, Curtis-McCarthy P, et al. Pulmonary alveolar proteinosis: clinical features and outcomes. Chest 1998; 114:1357.</a></li><li><a class="nounderline abstract_t">Kim C, Garcia-Tome R, Hurtado C, et al. Characteristics of hospital admissions for pulmonary alveolar proteinosis: analysis of the nationwide inpatient sample (2012-2014). BMC Pulm Med 2022; 22:365.</a></li><li><a class="nounderline abstract_t">Shah PL, Hansell D, Lawson PR, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000; 55:67.</a></li><li><a class="nounderline abstract_t">Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med 2011; 105:1908.</a></li><li><a class="nounderline abstract_t">Campo I, Mariani F, Rodi G, et al. Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet J Rare Dis 2013; 8:40.</a></li><li class="breakAll">Luisetti M, Trapnell BC. Pulmonary alveolar proteinosis. In: Interstitial lung disease, 5th, Schwarz MI, King TE Jr. (Eds), People's Medical Publishing House, Shelton, CT 2011. p.1079.</li><li><a class="nounderline abstract_t">Demirer E, Okutan O, Taş D, et al. Pulmonary alveolar proteinosis in Turkey: a review of twenty four cases. Turk Gogus Kalp Dama 2013; 21:723.</a></li><li><a class="nounderline abstract_t">Hawkins P, Chawke L, Cormican L, et al. Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings. Lancet 2021; 398:e7.</a></li><li><a class="nounderline abstract_t">Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 1994; 73:103.</a></li><li><a class="nounderline abstract_t">Martin RJ, Rogers RM, Myers NM. PUlmonary alveolar proteinosis: shunt fraction and lactic acid dehydrogenase concentration as aids to diagnosis. Am Rev Respir Dis 1978; 117:1059.</a></li><li><a class="nounderline abstract_t">Honda Y, Takahashi H, Shijubo N, et al. Surfactant protein-A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Chest 1993; 103:496.</a></li><li><a class="nounderline abstract_t">Kuroki Y, Tsutahara S, Shijubo N, et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 1993; 147:723.</a></li><li><a class="nounderline abstract_t">Honda Y, Kuroki Y, Shijubo N, et al. Aberrant appearance of lung surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance. Respiration 1995; 62:64.</a></li><li><a class="nounderline abstract_t">Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152:1860.</a></li><li><a class="nounderline abstract_t">Hirakata Y, Kobayashi J, Sugama Y, Kitamura S. Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. Eur Respir J 1995; 8:689.</a></li><li><a class="nounderline abstract_t">Fujishima T, Honda Y, Shijubo N, et al. Increased carcinoembryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Respiration 1995; 62:317.</a></li><li><a class="nounderline abstract_t">Usui Y, Takayama S, Nakayama M, et al. Interstitial lattice shadow and mediastinal lymphadenopathy with an elevation of carcinoembryonic antigen in severe pulmonary alveolar proteinosis. Intern Med 1992; 31:422.</a></li><li><a class="nounderline abstract_t">Lin FC, Chen YC, Chang SC. Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis. Mayo Clin Proc 2008; 83:1344.</a></li><li><a class="nounderline abstract_t">Claypool WD, Rogers RM, Matuschak GM. Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest 1984; 85:550.</a></li><li><a class="nounderline abstract_t">Miller PA, Ravin CE, Smith GJ, Osborne DR. Pulmonary alveolar proteinosis with interstitial involvement. AJR Am J Roentgenol 1981; 137:1069.</a></li><li><a class="nounderline abstract_t">Hudson AR, Halprin GM, Miller JA, Kilburn KH. Pulmonary interstitial fibrosis following alveolar proteinosis. Chest 1974; 65:700.</a></li><li><a class="nounderline abstract_t">Ishii H, Trapnell BC, Tazawa R, et al. Comparative study of high-resolution CT findings between autoimmune and secondary pulmonary alveolar proteinosis. Chest 2009; 136:1348.</a></li><li><a class="nounderline abstract_t">Johkoh T, Itoh H, Müller NL, et al. Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings. Radiology 1999; 211:155.</a></li><li><a class="nounderline abstract_t">Maimon N, Paul N, Downey GP. Progressive dyspnea associated with a crazy-paving appearance on a chest computed tomography scan. Can Respir J 2006; 13:269.</a></li><li><a class="nounderline abstract_t">Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166:215.</a></li><li><a class="nounderline abstract_t">Hwang JA, Song JH, Kim JH, et al. Clinical significance of cigarette smoking and dust exposure in pulmonary alveolar proteinosis: a Korean national survey. BMC Pulm Med 2017; 17:147.</a></li><li><a class="nounderline abstract_t">Chou CW, Lin FC, Tung SM, et al. Diagnosis of pulmonary alveolar proteinosis: usefulness of papanicolaou-stained smears of bronchoalveolar lavage fluid. Arch Intern Med 2001; 161:562.</a></li><li><a class="nounderline abstract_t">Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009; 113:2547.</a></li><li><a class="nounderline abstract_t">Lin FC, Chang GD, Chern MS, et al. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax 2006; 61:528.</a></li><li><a class="nounderline abstract_t">Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105:342.</a></li><li><a class="nounderline abstract_t">Luisetti M, Rodi G, Perotti C, et al. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 2009; 33:1220.</a></li><li><a class="nounderline abstract_t">Kariman K, Kylstra JA, Spock A. Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years. Lung 1984; 162:223.</a></li><li><a class="nounderline abstract_t">Milleron BJ, Costabel U, Teschler H, et al. Bronchoalveolar lavage cell data in alveolar proteinosis. Am Rev Respir Dis 1991; 144:1330.</a></li><li><a class="nounderline abstract_t">Rubinstein I, Mullen JB, Hoffstein V. Morphologic diagnosis of idiopathic pulmonary alveolar lipoproteinosis-revisited. Arch Intern Med 1988; 148:813.</a></li><li><a class="nounderline abstract_t">Burkhalter A, Silverman JF, Hopkins MB 3rd, Geisinger KR. Bronchoalveolar lavage cytology in pulmonary alveolar proteinosis. Am J Clin Pathol 1996; 106:504.</a></li><li><a class="nounderline abstract_t">Masuda T, Shimura S, Sasaki H, Takishima T. Surfactant apoprotein-A concentration in sputum for diagnosis of pulmonary alveolar proteinosis. Lancet 1991; 337:580.</a></li><li><a class="nounderline abstract_t">Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest 1997; 111:460.</a></li><li><a class="nounderline abstract_t">Prather AD, Smith TR, Poletto DM, et al. Aspiration-related lung diseases. J Thorac Imaging 2014; 29:304.</a></li></ol></div><div id="topicVersionRevision">Topic 4373 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13552931" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27514590" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary Alveolar Proteinosis Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29397349" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20338813" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The molecular basis of pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358702" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Surfactant proteins in pulmonary alveolar proteinosis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8163685" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11171752" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Focal congenital alveolar proteinosis associated with abnormal surfactant protein B messenger RNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11940594" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23997037" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Respiratory insufficiency in a newborn with congenital hypothyroidism due to a new mutation of TTF-1/NKX2.1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5775743" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acute silico-proteinosis. A new pathologic variant of acute silicosis in sandblasters, characterized by histologic features resembling alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6465685" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pulmonary alveolar proteinosis and aluminum dust exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7606971" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pulmonary alveolar proteinosis in a painter with elevated pulmonary concentrations of titanium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3553760" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858425" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pulmonary alveolar proteinosis in association with household exposure to fibrous insulation material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019344" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pulmonary alveolar proteinosis in workers at an indium processing facility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22207675" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Indium lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26344632" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary Alveolar Proteinosis, Barbecue Smoke, and Granulocyte-macrophage Colony-stimulating Factor Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282812" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27099254" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Alveolar proteinosis associated with aluminium dust inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8118651" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202325" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27799394" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25300566" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Secondary pulmonary alveolar proteinosis in hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26264606" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19465834" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Secondary pulmonary alveolar proteinosis: a confusing and potentially serious complication of hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162733" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21217786" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulmonary alveolar proteinosis following allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12111790" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acquired pulmonary alveolar proteinosis after umbilical cord blood transplantation for acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21920929" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Indium-tin oxide does not induce GM-CSF autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185750" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulmonary alveolar proteinosis associated with dust inhalation: not secondary but autoimmune?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713641" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary alveolar proteinosis in workers at an indium processing facility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25295756" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Early changes in clinical, functional, and laboratory biomarkers in workers at risk of indium lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8171324" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609219" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10198353" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14695413" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764326" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7697542" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9410898" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706504" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : GM-CSF and GM-CSF beta c receptor in adult patients with pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955567" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955570" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10499925" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512323" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10934102" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serological diagnosis of idiopathic pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12356582" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618581" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179134" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202348" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287477" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287475" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pulmonary alveolar proteinosis--is host defense awry?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20042763" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20224064" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12805087" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21318986" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25212679" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8810625" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bronchoalveolar lavage fluid composition in alveolar proteinosis. Early changes after therapeutic lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3769565" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2930063" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Improvement in alveolar macrophage migration after therapeutic whole lung lavage in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15467318" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rare infiltrative lung diseases: a challenge for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289783" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11377971" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The molecular bases of cystinuria and lysinuric protein intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8192561" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Abnormal pulmonary macrophages in lysinuric protein intolerance. Ultrastructural, morphometric, and x-ray microanalytic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8163273" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24227816" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34089740" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pulmonary Manifestations of GATA2 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24127487" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28916727" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Inflammatory responses induce an identity crisis of alveolar macrophages, leading to pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11312196" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : CT features of pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824014" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pulmonary alveolar proteinosis: clinical features and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36153570" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Characteristics of hospital admissions for pulmonary alveolar proteinosis: analysis of the nationwide inpatient sample (2012-2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10607805" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900000" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23497546" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Assessment and management of pulmonary alveolar proteinosis in a reference center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23497546" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Assessment and management of pulmonary alveolar proteinosis in a reference center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pulmonary alveolar proteinosis in Turkey: a review of twenty four cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34274066" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Autoimmune pulmonary alveolar proteinosis: a discrepancy between symptoms and CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8152364" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Isolation of mycobacteria in patients with pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/666104" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : PUlmonary alveolar proteinosis: shunt fraction and lactic acid dehydrogenase concentration as aids to diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432143" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Surfactant protein-A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8442609" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7784711" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Aberrant appearance of lung surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8520747" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7656937" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8552862" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Increased carcinoembryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1611200" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Interstitial lattice shadow and mediastinal lymphadenopathy with an elevation of carcinoembryonic antigen in severe pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19046553" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368143" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6975003" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pulmonary alveolar proteinosis with interstitial involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4832278" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pulmonary interstitial fibrosis following alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19892674" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Comparative study of high-resolution CT findings between autoimmune and secondary pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10189465" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896429" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Progressive dyspnea associated with a crazy-paving appearance on a chest computed tomography scan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12119235" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pulmonary alveolar proteinosis: progress in the first 44 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29162083" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Clinical significance of cigarette smoking and dust exposure in pulmonary alveolar proteinosis: a Korean national survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11252115" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Diagnosis of pulmonary alveolar proteinosis: usefulness of papanicolaou-stained smears of bronchoalveolar lavage fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19282464" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16517574" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12498816" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19407056" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Plasmapheresis for treatment of pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6492867" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1741546" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Bronchoalveolar lavage cell data in alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3355301" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Morphologic diagnosis of idiopathic pulmonary alveolar lipoproteinosis-revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8853040" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Bronchoalveolar lavage cytology in pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1671943" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Surfactant apoprotein-A concentration in sputum for diagnosis of pulmonary alveolar proteinosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041997" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Diagnosing pulmonary alveolar proteinosis. A review and an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24911122" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Aspiration-related lung diseases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
